Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

Viral Hepatitis


Quick Links

Veterans Crisis Line Badge
My healthevet badge
EBenefits Badge

Management and Treatment of Hepatitis C Viral Infection: Table 7

for Health Care Providers

Table 7.Comparison of Sustained Virologic Response Rates (SVR) for Peginterferon Alfa-2b and Interferon Alfa Combination Therapies Given Over 48 Weeks

Back to Tables

* Peginterferon alfa-2b 1.5 mcg/kg/wk and ribavirin 800 mg/day.

IFN 3 million U three times weekly plus ribavirin 1,000 or 1,200 mg/day.

Compared to interferon alfa plus ribavirin.

§Defined as >2 million copies/mL (NGI, sensitivity 100 copies/mL); equivalent to >800,000 IU/mL.

Statistical analysis not performed; data from Peg-Intron package insert.

||Defined as ≤2 million copies/mL (NGI, sensitivity 100 copies/mL); equivalent to ≤800,000 IU/mL.

Peginterferon alfa-2b plus ribavirin*Interferon alfa plus ribavirin
Overall54% (p=0.01)47%
HCV genotype 142% (p<0.05)33%
High viral
Low viral
Not reportedNot reported
HCV genotype 2 or 382%79%
HCV genotypes 4-650%38%